Kornimate/medical-research-clean huggingface dataset:
pulmonary mr angiography and lower extremity mr venous imaging using gadofosveset (ablavar)

Conditions: Pulmonary Embolism

Summary: the use of the contrast agent, ablavar, will help with the diagnosis of pulmonary embolism in magnetic resonance imaging (mri).

specific aim 1: to assess first-pass snr and cnr of pulmonary mr angiography performed with 0.03 mmol/kg of intravenous gadofosveset trisodium. hypothesis: use of 0.03 mmol/kg of gadofosveset trisodium in gradient recalled echo pulmonary mr angiography will provide a pulmonary artery snr and cnr equal to or better than the snr and cnr obtained using the same mr technique with 0.2 mmol/kg of a conventional contrast agent (gadopentetate dimeglumine) and equal to or better than 0.1 mmol/kg of intravenous gadobenate dimeglumine. data will be compared to snr and cnr of pulmonary mr angiogram images obtained at washington university as part of the pioped iii study. specific aim 2: to assess snr and cnr of breath-hold pulmonary mr imaging obtained immediately after the original first-pass breath-hold pulmonary mr angiography. hypothesis: snr and cnr of pulmonary mr angiography performed immediately after first-pass breath-hold pulmonary mr angiography will be at least equal to the snr and cnr obtained using the same mr technique with 0.2 mmol/kg of a conventional contrast agent (gadopentetate dimeglumine) and at least equal to 0.1 mmol/kg of intravenous gadobenate dimeglumine. specific aim 3: to assess snr and cnr of lower extremity mr venogram (mrv) performed immediately after the two pulmonary mr angiograms, described above. hypothesis: snr and cnr of passive lower extremity mrv performed after pulmonary mr angiography will be equal to or better than the snr and cnr obtained using the same passive mrv technique with 0.2 mmol/kg of a conventional contrast agent or 0.1 mmol/kg of gadobenate dimeglumine. again, data will be compared to snr and cnr of lower extremity

Eligibility criteria:
inclusion criteria: 1. patient that have pulmonary embolism. 2. 18 yrs of age and older exclusion criteria: 1. allergy to gadolinium based contrast. 2. allergy to iodated based contrast. 3. renal insufficiency (gfr \< 60 ml/min?1.73m2) 4. pregnant or nursing 5. contraindication to mri

Keywords: pulmonary embolism contrast agent
evaluation of a cosmetic product to preserve skin conditions when using anti-egfr cancer therapies

Conditions: Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms

Summary: it is important for patients treated with anti-egfr therapies to get access to cosmetic options to preserve their skin condition during treatment. anti-egfr therapies are known to fragilize epidermis and to provoke rashes; which often lead to treatment discontinuation. the aim of this study is to demonstrate that the onco-rash cream is able to preserve skin condition without side effects. decreasing skin toxicity is expected to improve patients' life and facilitate treatment follow-up.


Eligibility criteria:
inclusion criteria: * patient \> 18 years old * patient naive from anti-egfr treatment (gefitinib, erlotinib, afatinib, cetuximab panitumumab, osimertinib, alectinib et crizotinib, etc). * nsclc (non-small cell lung cancer) patients eligible to anti-egfr as first line treatment (gefitinib, erlotinib,afatinib, etc) * colorectal cancer patients eligible to anti-egfr as first line treatment (cetuximab, panitumumab,....) * head and neck/ent (ear, nose troat) cancer patients eligible to anti-egfr as first line treatment (cetuximab,...) * signed informed consent * social security affiliation exclusion criteria: * pregnant or breastfeeding patient * patient in age to procreate without an efficient contraceptive method * patient with previous experience of allergic or irritative contact dermatitis to components of the studied product * patient with dermatologic conditions that cannot permit the study of skin toxicity of anti-egfr * patients under radiotherapy 8 days prior the inclusion date * patient under immunotherapy 8 days prior the inclusion date * patient with local or systemic antibiotic treatment for acne 8 days prior the inclusion date * patient with antihistamines treatment 8 days prior the inclusion date * patients taking nsaids or corticoids as chronic medication or that took nsaids or corticoids 5 days prior the inclusion date * participation to another interventional study * patient with an altered ecog (eastern cooperative oncology group) state ( \>2) * patient deprived of liberty or subjected to guardianship * impossibility to track and follow patient for geographical, social or psychiatric reasons.

Keywords: skin rash anti-egfr therapy cosmetic product acne cancer patients
deep learning model for pure solid nodules classification

Conditions: Lung Cancer

Summary: the purpose of this study is to compare the predictive performance of a ct-based deep learning model for pure-solid nodules classification and compared with the tumor maximum standardized uptake value on pet in a multicenter prospective cohort.


Eligibility criteria:
inclusion criteria: * participants scheduled for surgery for radiological finding of pulmonary pure-solid lesions from the preoperative thin-section ct scans; * the maximum short-axis diameter of lymph nodes less than 3 cm on ct scan; * age ranging from 18-75 years; * definied pathological examination report available; * obtained written informed consent. exclusion criteria: * multiple lung lesions; * poor quality of ct images; * participants with incomplete clinical information; * participants who have received neoadjuvant therapy before initial ct evaluation.

Keywords: deep learning model pure-solid nodules pet-ct
a study to evaluate efficacy of dotinurad and febuxostat for the treatment of participants with gout

Conditions: Gout

Summary: the primary purpose of the study is to confirm the efficacy of dotinurad 4 milligram (mg) to febuxostat 40 mg on the percentage of participants achieving a serum uric acid (sua) level less than or equal to (\<=) 6.0 milligrams per deciliter (mg/dl) at week 24 in chinese participants with gout.


Eligibility criteria:
inclusion criteria: 1. gout participant (with a history of gout attack or concurrent gouty tophi) with sua level greater than (\>) 7.0 mg/dl in the screening phase (within 14 days prior to randomization) 2. male or female participant with age greater than or equal to (\>=) 18 years at the time of informed consent 3. provide written informed consent signed by the participant prior to entering the study or undergoing any study procedures, indicating that they understand the purpose and procedures required for the study and are willing to participate in the study exclusion criteria: 1. has gouty arthritis that has not resolved within 14 days prior to randomization 2. has secondary hyperuricemia 3. comorbidities with nephrolithiasis or clinical urinary calculi (example, haematuria, back pain) 4. evidence of clinically significant disease (example, cardiac disease: heart failure and angina unstable, respiratory, gastrointestinal, renal, or neurological disease: cerebral infarction) that in the opinion of the investigator could affect the participant's safety or interfere with the study assessments 5. evidence of clinical significant hepatic disease: refer to grade 2 in the "seriousness grading criteria for adverse drug reactions" or aspartate aminotransferase (ast) or alanine aminotransferase (alt) \>3 multiple (\*) upper limit of normal (uln) in the screening phase 6. estimated glomerular filtration rate (egfr) of less than (\<) 30 milliliter per minute/1.73 square meters in the screening phase 7. systolic blood pressure of \>=180 millimetre of mercury (mmhg) or diastolic blood pressure of \>=110 mmhg in the screening phase 8. hemoglobin a1c national glycohemoglobin standardization program (ngsp) value of \>=8.4 percent (%) in the screening phase 9. hypersensitivity to the study drugs (dotinurad or febuxostat) or their excipients, or all of urine alkalinizer (potassium citrate/sodium citrate hydrate compound preparations)

Keywords: dotinurad febuxostat
comparison of bone mineral loss in prostate cancer patients who is receiving gnrh agonist and -plus anti-androgen agent

Conditions: GnRH Agonist Alone vs. GnRH Agonist Plus Anti-androgen Combination Treated Prostate Cancer Patients

Summary: comparison of bone mineral loss in prostate cancer patients who is receiving gnrh agonist and -plus anti-androgen agent

mc md

Eligibility criteria:
inclusion criteria: * korean prostate cancer over 50 years old with pathological confirmation * patients receiving gnrh antagonist or gnrh agonist plus anti- androgen combination within 6 months since starting. * patients measured bone density level before starting to receive hormone therapies above. exclusion criteria: * patients who are treated other anti-osteoporosis drugs and who are treated bisphosphate due to bmd t score below -3.0. * patients who are hard to be analysed by attach to other bone disease. * patients who are hard to be analysed by limitation of chart record according to investigators'discretion.

Keywords: bone mineral loss prostate cancer gnrh agonist alone vs. gnrh agonist plus anti-androgen combination
anesthetic management for ta-bsm in hocm

Conditions: Anesthesia; Transapical Beating-heart Septal Myectomy; Hypertrophic Cardiomyopathy

Summary: to retrospectively analyze the preoperative, intraoperative and postoperative anesthesia management of patients with hypertrophic cardiomyopathy undergoing ta-bsm in the investigators' hospital, and to provide clinical basis for the development of reasonable and standardized perioperative anesthesia program for these patients.

hypertrophic obstructive cardiomyopathy is an inherited cardiomyopathy. such patients have significantly reduced mobility and quality of life, and are prone to sudden death in severe cases. according to conservative estimates, there are about 2 to 5 million patients with hypertrophic heart disease in china, and about 15 to 20 million patients in the world, which seriously threatens human health. the traditional surgical treatment is partial ventricular septal myectomy through thoracotomy, which is traumatic and difficult, with poor efficacy and high operative mortality in hospitals with little experience. in order to solve this problem, professor wei's team invented and developed a beating-heart myectomy device, and established the first transapical beating-heart septal myectomy (ta-bsm) with the aid of this device through the apical minimally invasive incision under the guidance of esophageal ultrasound. with the help of echocardiography, the position of the rotator can be monitored in real time, and the angle and thickness of the rotator can be determined to ensure the safe removal of the hypertrophic ventricular septum, so as to solve the problem of left ventricular outflow tract obstruction. the team firstly completed 47 clinical trials from april to september 2022, with a surgical success rate of 97.9%. at 3-month follow-up, the median maximum pressure gradient of left ventricular outflow tract decreased from perioperational 86 mmhg to postoperational 19 mmhg , and 45 participants (95.7%) had complete remission of mitral regurgitation. all patients showed significant improvement or even disappearance of symptoms, and exercise capacity and quality of life were significantly improved. since ta-bsm is a new surgical method, there is no unified standard for anesthesia management and lack of evidence-based evidence. therefore, the aim of this study is to retrospectively analyze the preoperative, intraoperative and postoperative anesthetic management of participants with hypertrophic cardiomyopathy undergoing ta-bsm, so as to provide clinical basis for formulating reasonable and standardized perioperative anesthesia programs for these patients.

Eligibility criteria:
inclusion criteria: * patients with hypertrophic cardiomyopathy * american society of anesthesiologists (asa) physical status classification i-iii * undergoing ta-bsm exclusion criteria: * cardiopulmonary bypass was used to assist the surgery.
study of efficacy and safety of buparlisib (bkm120) plus paclitaxel versus placebo plus paclitaxel in recurrent or metastatic head and neck cancer previously pre-treated with a platinum therapy

Conditions: Head and Neck Squamous Cell Carcinoma

Summary: phase ii study of efficacy and safety of buparlisib (bkm120) plus paclitaxel versus placebo plus paclitaxel in recurrent or metastatic head and neck cancer previously pre-treated with a platinum therapy.the primary endpoint was pfs and the key secondary endpoint was overall survival.


Eligibility criteria:
inclusion criteria: * patient has histologically/cytologically-confirmed hnscc. * patient has archival or fresh tumor tissue for the analysis of pi3k-related biomarkers. one tumor block (preferred) or a minimum of 12 unstained slides to be provided. enrollment in the study is contingent on confirmation of an adequate amount of tumor tissue. * patients with recurrent or metastatic disease resistant to platinum-based chemotherapy (defined as progression while on platinum-based chemotherapy given in the recurrent/metastatic setting). pretreatment with cetuximab is allowed * measurable disease as determined by per recist criteria v1.1. if the only site of measurable disease is a previously irradiated lesion, documented progression of disease and a 4 week period since radiotherapy completion is required * adequate bone marrow function and organ function * ecog performance status ≤ 1 exclusion criteria: * patient has received previous treatment with any akt, mtor inhibitors or pi3k pathway inhibitors; * patient treated with more than one prior chemotherapy regimen for recurrent/metastatic disease * patient has symptomatic cns metastases. patients with asymptomatic cns metastases may participate in this trial. the patient must have completed any prior local treatment for cns metastases ≥ 28 days prior to the start of study treatment (including radiotherapy and/or surgery) and must have stable low dose of corticosteroid therapy; * patient has not recovered to ≤ grade 1 (except alopecia) from related side effects of any prior antineoplastic therapy * patient has any of the following cardiac abnormalities:symptomatic congestive heart failure, history of documented congestive heart failure (new york heart association functional classification iii-iv), documented cardiomyopathy, left ventricular ejection fraction (lvef) \ 480 msec on the screening ecg (using the qtcf formula);

Keywords: platinum pre-treated recurrent or metastatic head and neck squamous cell carcinoma recurrent metastatic bkm120
effect of a cardiovascular health promotion program in youth - the tyrolean early vascular ageing-study

Conditions: Atherosclerosis; Life Style

Summary: atherosclerosis - the main cause of cardiovascular diseases - starts already in childhood. the tyrolean early vascular ageing-study aims to improve the vascular health of tyrolean adolescents by a multi-layer intervention program.

cardiovascular diseases (cvds) are the leading non-communicable cause of death. primary prevention measures aim to improve the awareness of the individual risk profile and promote healthy lifestyle. multiple evaluations have shown, that atherosclerosis - the main cause of cvds - begins already early in life. therefore, prevention programs have to start already in childhood. the eva-tyrol study is a prospective, biomedical cohort study. 2000 participants will be recruited from high schools and training companies spread over north- and east-tyrol (austria) and south-tyrol (italy). for the 1500 participants included in the intervention group two examinations will be scheduled within a two-year interval. participants will be in the 10th grade (mean age, 15-16 years) at the baseline and in the 12th grade (mean age, 17-18 years) at the follow-up examination. 500 participants in the 12th grade without participation in a health promotion program will serve as a control group. the 2000 participants equal roughly 5% of the tyrolean population of the included age-group. medical examination includes an extensive questionnaire, anthropometric measurements, fasting blood sampling, high-resolution ultrasound of the common carotid artery, and carotid-femoral pulse wave velocity. active intervention will consist of (1) enhancing knowledge about cvds, (2) individual medical counseling based on the results of the baseline examination, (3) providing an online health promotion tool and (4) involvement of participants in planning and conduction of health promotion projects. main outcome parameter is the difference in the number of ideal health metrics as defined by the american heart association between the intervention and control group. this study aims to improve cardiovascular health in tyrolean adolescents and to evaluate the efficacy of this multi-layer health promotion program. moreover, the investigators expect numerous insights in the prevalence of vascular risk conditions and early vascular pathologies in adolescents.

Eligibility criteria:
inclusion criteria: * intervention group: participants must be in 10th school grade or aged 15 to 16 years when recruited in training companies. * control group: participants must be in 12th school grade or aged 17 to 18 years when recruited in training companies. exclusion criteria: - none
longitudinal cardiac outcomes and body composition

Conditions: Cardiovascular Diseases; Heart Diseases; Hypertension

Summary: to relate cardiac structure and blood pressure (bp) elevation in adults to childhood bp and body size and composition.

background: to describe growth events adequately, long-term serial data with frequent measurements at appropriate ages are necessary. the study uses the fels longitudinal study. in the fels longitudinal study, data collection begins at birth, and all children are scheduled for measurements semiannually, on their birthdays and half birthdays, until the age of 18 years, after which they are scheduled every 2 years. the fels study is unique with a rich 70-year history of ongoing serial data collection enabling the analysis of relationships of variables collected in childhood to cardiovascular risk factors well into late adulthood. design narrative: the study will link adult cardiac structure and hemodynamic function with long-term serial childhood data for body size, body composition and blood pressure. to address this goal, 685 adult white active participants in the fels longitudinal study, 352 men and 333 women 20 to 70 years of age, will be studied. these adults were selected based on the availability of serial body size data from 2 to 18 years and serial body composition data from 8 to 18 years. echo cardiographic data for cardiac structure and hemodynamic parameters will be collected from these 685 adults using well defined procedures with a well established quality control and assurance program. the availability of the long-term childhood records of these fels participants for body size and composition provides a unique opportunity to relate childhood data to subsequent adult data for cardiac structure and blood pressure. the innovative longitudinal statistical analysis used will include covariates such as age, gender, birth year for secular trend, adulthood lifestyle (smoking, alcohol consumption, and physical activity), adult body size and composition, menopause, and medical condition and medication use. the analysis of the hypotheses in this study links cardiac structure and hemodynamic parameters in adulthood to childhood growth and body composition. such linkages will reveal how various growth and body composition profiles and patterns during childhood can lead either to pathological or to healthy cardiac structure and hemodynamic parameters in adulthood. understanding adult cardiac outcomes in response to changes in fat and fat-free mass from childhood into adulthood will provide important clues about potential physiologic mechanisms underlying the observed changes in body mass index (bmi). elucidating adverse relationships through such a linkage can lead to the early identification of children at high risk for adult cardiovascular disease. this investigation will relate direct measures of body composition to adult cardiac structure and hemodynamic parameters.

Eligibility criteria:
no eligibility criteria
s0000 selenium and vitamin e in preventing prostate cancer

Conditions: Prostate Cancer

Summary: rationale: chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. it is not yet known which regimen of selenium and/or vitamin e may be more effective in preventing prostate cancer. purpose: randomized phase iii trial to determine the effectiveness of selenium and vitamin e, either alone or together, in preventing prostate cancer.

objectives: * compare the effect of selenium and vitamin e administered alone vs in combination on the clinical incidence of prostate cancer. * compare the effect of these prevention regimens on the incidence of lung cancer, colorectal cancer, and all cancers combined in participants on this study. * compare the effect of these prevention regimens on prostate cancer-free survival, lung cancer-free survival, colorectal cancer-free survival, cancer-free survival, overall survival, and serious cardiovascular events in these participants.

Eligibility criteria:
disease characteristics: * healthy male volunteers * digital rectal examination (dre) deemed not suspicious for prostate cancer performed within 364 days prior to study entry * participants with a suspicious dre are ineligible even if a recent or subsequent biopsy is negative for cancer * total prostate-specific antigen ≤ 4.0 ng/ml within 364 days prior to study entry * no prior prostate cancer or high-grade (grade 2-3) prostatic intraepithelial neoplasia patient characteristics: age: * see disease characteristics performance status: * not specified life expectancy: * not specified hematopoietic: * not specified hepatic: * not specified renal: * not specified cardiovascular: * systolic blood pressure \< 160 mm hg * diastolic blood pressure \< 90 mm hg * no history of hemorrhagic stroke other: * no malignancies within the past 5 years except basal cell or squamous cell skin cancer * no uncontrolled medical illness * no retinitis pigmentosa prior concurrent therapy: biologic therapy * not specified chemotherapy * not specified endocrine therapy * not specified radiotherapy * not specified surgery * not specified other * at least 7 years since prior randomization to swog-9217, with completion of end-of-study biopsy requirement * no additional concurrent selenium or vitamin e (contained in individual supplements, antioxidant mix, or multivitamin) * concurrent multivitamins allowed (supplied on study) * no concurrent anticoagulation therapy (e.g., warfarin) * concurrent prophylactic aspirin (average daily dose no greater than 175 mg/day) allowed * concurrent daily aspirin dose ≤ 81 mg for participants receiving clopidogrel * concurrent anti-hypertension medication allowed * no concurrent participation in another study involving a medical, surgical, nutritional, or life-style intervention (unless no longer receiving the intervention and are in the follow-up phase only)

Keywords: prostate cancer
a prospective study evaluating seroprevalence and seroconversion of antibodies against adeno-associated virus (aav)

Conditions: Hemophilia A

Summary: a prospective cohort study utilizing biospecimen sample collection from adult hemophilia a subjects to evaluate and characterize seroprevalence and the seroconversion of antibodies against aav serotypes

this is a multinational, multi-center, prospective cohort study utilizing biospecimen sample collection from adult hemophilia a subjects to evaluate and characterize seroprevalence and the seroconversion of antibodies against aav serotypes

Eligibility criteria:
inclusion criteria: * adult subjects with hemophilia a exclusion criteria: * subject previously treated with aav vector gene therapy